



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Friday, November 27, 2009

Sciele Pharma

[View the current Sciele Pharma Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/32578-Sciele+Pharma.html)

(<http://www.bioportfolio.com/biocorporate/32578-Sciele+Pharma.html>)

Contact Details:

Five Concourse Parkway Suite 1800

Atlanta

Georgia

30328

United States of America

Tel: (800) 461-3696

Fax:

Email: ir@sciele.com

Sciele Pharma, Inc. (NASDAQ:SCRX), formerly known as First Horizon Pharmaceutical Corp., is a pharmaceutical company specializing in sales, marketing, and the development of branded prescription products focused on Cardiovascular/Metabolic and Women's Health. The Company's cardiovascular/metabolic products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina, and type 2 diabetes, and its Women's Health products are designed to improve the health and well-being of women and their babies. Headquartered in Atlanta, Georgia, and founded in 1992, Sciele Pharma employs more than 700 people, including approximately 525 sales representatives. The Company's success is based on placing the needs of patients first, improving health and quality of life, and implementing its business platform – an Entrepreneurial Spirit, Innovation, Speed of Execution, Simplicity and Teamwork.

Press Releases on Sciele Pharma:

"As an Industry, We've Been too Focused on Regulatory Approval," Says Solvay Pharmaceuticals Eric Rambeaux at the Pharma Marketing Summit.	26th November, 2009		<i>LONDON, November 26 /PRNewswire/ -- Rambeaux joined a host of other industry leaders at eyeforpharma's 9th annual Pharma Marketing Summit 2009 conference in Berlin, where several key themes</i>
Cytochroma to Present at 21st Annual Piper Jaffray Health Care Conference	25th November, 2009	Cytochroma	<i>MARKHAM, ON, Nov. 25 /PRNewswire/ - Cytochroma today announced that Charles W. Bishop, PhD, President and CEO, will be presenting a corporate overview at the 21st Annual Piper Jaffray Health Care</i>

[Cytochroma Announces Appointment of Peter Moldt to Board of Directors](#)

25th November, 2009

Cytochroma

MARKHAM, ON, Nov. 25 /PRNewswire/ - Cytochroma today announced the appointment of Peter Moldt, PhD to its Board of Directors. Dr. Moldt will replace Mr. Ulrik Spork as the Novo A/S representative on

[Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis](#)

25th November, 2009

Reportlinker

NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Intranasal Drug Delivery - US Market Trends & Analysis <http://www>

[Reportlinker Adds Regenerative Medicine - Global Market Trends](#)

25th November, 2009

Reportlinker

NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Regenerative Medicine - Global Market Trends <http://www.reportlinker.com>

BioNews Results for Sciele Pharma



- [Penis Spray Makes Men Last Longer](#)
WebMD: Nov 20 2009 8:28PM Matching: sciele pharma
- [Medical News: Pivotal Study For PSD502--The First Potential Treatment For Premature Ejaculation](#)
BioFind: Nov 20 2009 12:57PM Matching: sciele pharma
- [Data from second positive pivotal study of PSD502 for treatment of PE presented](#)
News-Medical.Net: Nov 20 2009 6:00AM Matching: sciele pharma
- [Sciele Pharma, a Shionogi Company, Presents Pivotal Study for PSD502 The First Potential Treatment for Premature Ejaculation At the Sexual Medicine](#)
Yahoo! Canada: Nov 19 2009 2:36PM Matching: sciele pharma
- [Pivotal Study for PSD502--The First Potential Treatment for Premature Ejaculation](#)
Newswise: Nov 19 2009 4:15PM Matching: sciele pharma
- [Sciele Pharma, a Shionogi Company, Presents Pivotal Study for PSD502 - The First Potential Treatment for Prema](#)
Business Wire via Yahoo!: Nov 19 2009 1:37PM Matching: sciele pharma
- [Sciele Pharma, a Shionogi Company, Presents Pivotal Study for PSD502 EUR The First Potential Treatment for Pr](#)
Business Wire: Nov 19 2009 1:33PM Matching: sciele pharma
- [Sciele Pharma, a Shionogi Company, Presents Pivotal Study for PSD502 The First Potential Treatment](#)
PR inside: Nov 19 2009 1:27PM Matching: sciele pharma
- [Sciele Pharma, a Shionogi Company, Presents Pivotal Study for PSD502 EUR' The First Potential Treatment for P](#)
Business Wire: Nov 19 2009 1:23PM Matching: sciele pharma
- [Sciele Pharma, a Shionogi Company, Presents Pivotal Study for PSD502 - The First Potential Treatment for Prema](#)

- Street Insider: Nov 19 2009 1:21PM Matching: sciele pharma*
- [Sciele Pharma, a Shionogi Company, Presents Pivotal Study for PSD502 - The First Potential Treatment for Prema](#)
Reuters: Nov 19 2009 1:54PM Matching: sciele pharma
 - [Positive results from Sciele Pharma's second pivotal study of PSD502 for the treatment of PE](#)
News-Medical.Net: Nov 19 2009 3:44PM Matching: sciele pharma
 - [Pivotal Study For Sciele Pharma, Inc. \(SCRX\)'s PSD502 -- The First Potential Treatment For Premature Ejaculati](#)
BioSpace: Nov 19 2009 7:19PM Matching: sciele pharma
 - [Pivotal study for PSD502 -- the first potential treatment for premature ejaculation](#)
Genetic Engineering News: Nov 19 2009 2:00PM Matching: sciele pharma
 - [Sciele Pharma, a Shionogi Company, to Purchase Addrenex Pharmaceuticals](#)
TradingMarkets: Nov 19 2009 4:53AM Matching: sciele pharma

Sciele Pharma Clinical Trials:



- [A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

